Synergistic Treatment System for Surgery-Induced Cachexia

Publication ID: 24-11857525_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Treatment System for Surgery-Induced Cachexia,” Published Technical Disclosure No. 24-11857525_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857525_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,525.

Summary of the Inventive Concept

A comprehensive system integrating AI, IoT, blockchain, and novel biomaterials to prevent and treat surgery-induced cachexia, enhancing patient outcomes and quality of life.

Background and Problem Solved

The original patent addressed the treatment of surgery-induced cachexia using specialized immunonutrition supplements. However, it did not account for the complexity of individual patient responses, limited data tracking, and the potential for more effective treatment combinations. The new inventive concept overcomes these limitations by incorporating cutting-edge technologies to create a personalized, data-driven, and synergistic treatment system.

Detailed Description of the Inventive Concept

The system comprises a wearable device for monitoring vital signs, a blockchain-based health record for secure data tracking, and an AI algorithm generating personalized treatment plans. The system administers a specialized immunonutrition supplement, which can be combined with novel biomaterial implants for enhanced wound healing. IoT-enabled sensors monitor and adjust the supplement's delivery in real-time based on the patient's physiological response. A machine learning model predicts patient outcomes, and a user interface provides healthcare providers with data-driven treatment recommendations.

Novelty and Inventive Step

The integration of AI, IoT, blockchain, and novel biomaterials with the original patented concept creates a new, non-obvious synergistic treatment system. The AI-driven analytics and IoT-enabled real-time monitoring introduce a level of personalization and adaptability not present in the original patent.

Alternative Embodiments and Variations

Alternative embodiments could include the use of different AI algorithms, varying IoT sensor configurations, or the incorporation of additional biomaterials. Variations could involve integrating the system with existing electronic health records or using different types of wearable devices.

Potential Commercial Applications and Market

The synergistic treatment system has significant commercial potential in the healthcare industry, particularly in the fields of surgical oncology, wound care, and personalized medicine. Target markets include hospitals, clinics, and healthcare providers seeking to improve patient outcomes and reduce treatment costs.

Field of Art

Medical nutrition, oncology, and digital health technologies with a focus on patient treatment systems for surgical interventions and metabolic disorders

Person of Ordinary Skill (PHOSITA) Profile

A professional with expertise in biomedical engineering, nutrition science, and digital health technologies, possessing advanced degrees and experience in developing patient monitoring and treatment systems

Obviousness Rationale

A PHOSITA would recognize that integrating digital monitoring technologies with established nutritional interventions represents a predictable extension of existing medical treatment methodologies. The combination of AI-driven personalization, IoT sensor monitoring, and blockchain data tracking with the source patent's specialized immunonutrition supplement creates a logical progression of treatment optimization strategies. The technical variations represent incremental improvements that would be apparent to a skilled practitioner seeking to enhance patient care through technological integration.

Obvious Combinations & Variations

Source Patent Element
Specialized immunonutrition supplement containing L-arginine, omega-3 fatty acids, and dietary nucleotides
PTD Variation
AI-driven personalized treatment algorithm for supplement administration based on real-time patient monitoring
Obviousness Reasoning
Applying machine learning to optimize nutritional interventions is a predictable application of known digital health technologies to existing medical treatments
Source Patent Element
Method of treating surgery-induced cachexia in patients with bladder cancer
PTD Variation
IoT-enabled sensor system for monitoring patient physiological responses and adjusting supplement delivery
Obviousness Reasoning
Implementing real-time monitoring and adaptive treatment delivery represents a standard approach to precision medicine that would be obvious to a PHOSITA
Source Patent Element
Composition for preventing myeloid-derived suppressor cells and pro-inflammatory cytokines
PTD Variation
Blockchain-based health record integration for secure tracking of patient treatment data and outcomes
Obviousness Reasoning
Utilizing blockchain for secure medical data management is a known technique for improving patient data tracking and treatment continuity
Source Patent Element
Nutritional supplement for surgical patients
PTD Variation
Novel biomaterial implants designed to complement the nutritional supplement and enhance wound healing
Obviousness Reasoning
Combining nutritional interventions with biomaterial technologies is a predictable approach to improving surgical patient outcomes
Source Patent Element
Treatment method for surgery-induced cachexia
PTD Variation
Comprehensive digital health system integrating wearable devices, AI analytics, and personalized treatment recommendations
Obviousness Reasoning
Developing comprehensive digital health solutions that integrate multiple monitoring and treatment technologies is an obvious progression in medical technology
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857525 and the disclosed technological variations, a person having ordinary skill in the art would find the claimed innovations obvious and lacking inventive step. The combination of known nutritional intervention strategies with digital health technologies represents a predictable application of existing medical and technological knowledge, thereby rendering the proposed innovations unpatentable under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,525
TitleTreatment or prevention of surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines
Assignee(s)SOCIÉTÉ DES PRODUITS NESTLÉ S.A.